Technology at Viafet

Viafet Genomics Laboratory's team is dedicated to providing unparalleled genetic testing services through expertise and investment in the latest technologies. To that end, Viafet has invested heavily in the most advanced genetic testing technologies available for in order to provide patients and providers with thorough, affordable and efficient testing. With genetic testing services in the United Arab Emirates (Dubai and Abu Dhabi), Australia, the Kingdom of Saudi Arabia, Lebanon and more locations coming soon, Viafet's services are available to a wide network of clinicians and patients.

Next Generation Sequencing (NGS)

Next Generation Sequencing (NGS) is the newest generation of genetics technology that has brought DNA sequencing to unprecedented speed, enabling impressive scientific achievements. Three NGS platforms are used in Viafet's laboratory, the MiSeq and 500Seq from illumina and the Ion Proton from Life Technology. At Viafet, NGS is used for 24-chromosome aneuploidy PGS, Personalized Medicine, Carrier Screening, Whole Exome Sequencing and Non-Invasive Prenatal Test (NIPT).

Sanger Sequencing

Before the development of NGS, Sanger Sequencing was the only available method of DNA sequencing. Sanger Sequencing allows for high accuracy results but at low throughput rates and for this reason, it is still used in the confirmation of some results made through NGS. At Viafet, Sanger Sequencing is completed with Capillary Electrophoresis 3500 by Life Technology, the last model of technology that will be developed for this technique. In instances of mutation screening where the genetic mutation is made up of few, known, exons, Sanger Sequencing is used for Targeted Mutation Screening.

Mircoarray based Comparative Genomic Hybridization (array-CGH)

Array-CGH compares a chromosome set to that of a normal standard in order to show if a person or embryo has any additional or missing chromosomes. Through Array-CGH, microdeletions and duplications of a certain size may also be detected. In 2008, Viafet established the protocol for array-CGH on a single cell allowing 24-chromosome PGS of embryos for the first time. In 2014, after being adopted as the array-CGH protocol of Agilent Technologies as GenetiSure, Viafet's protocol is utilized by scientists worldwide performing 24-chromosome PGS through array-CGH.

Fluorescence in situ hybridisation (FISH)

FISH is used in the detection of aneuploidy in embryos in chromosomes 13, 18, 21, X and Y through the use of fluorescent probes. FISH is mostly used in cases of gender selection and to avoid the most common chromosomal abnormalities seen in newborns.